Caroline Stokke1,2, Jakob Nordberg Nørgaard3,4, Hilde Feiring Phillips5, Alexander Sherwani5, Syed Nuruddin6, James Connelly5, Fredrik Schjesvold3,7, Mona-Elisabeth Revheim5,4. 1. Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. carsto@ous-hf.no. 2. Dep. of Physics, University of Oslo, Oslo, Norway. carsto@ous-hf.no. 3. Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway. 4. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 5. Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. 6. Norwegian Medical Cyclotron Centre, Oslo, Norway. 7. KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
Abstract
PURPOSE: [18F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, [18F]FDG PET has some limitations, and imaging with alternative tracers should be explored. In this study, we aimed to evaluate the performance of [18F]fluciclovine PET compared to [18F]FDG PET in newly diagnosed MM patients. PROCEDURES: Thirteen newly diagnosed transplant eligible MM patients were imaged both with [18F]FDG PET/CT and [18F]fluciclovine PET/CT within 1 week in a prospective study. The subjects were visually assessed positive or negative for disease. The number of lesions and the SUVmax of selected lesions were measured for both tracers. Furthermore, tracer uptake ratios were obtained by dividing lesion SUVmax by blood or bone marrow SUVmax. Between-group differences and correlations were assessed with paired t-tests and Pearson tests. Bone marrow SUVs were compared to bone marrow plasma cell percentage in biopsy samples. RESULTS: Nine subjects were assessed positively by [18F]FDG PET (69%) and 12 positives by [18F]fluciclovine PET (92%). All positive subjects had [18F]fluciclovine scans that were qualitatively scored as easier to interpret visually than the [18F]FDG scans. The number of lesions was also higher; seven of nine subjects with distinct hot spots on [18F]fluciclovine PET had fewer or no visible lesions on [18F]FDG PET. The mean lesion SUVmax values were 8.2 and 3.8 for [18F]fluciclovine and [18F]FDG, respectively. The mean tumour to blood values were 6.4 and 2.0 for [18F]fluciclovine and [18F]FDG, and the mean ratios between tumour and bone marrow were 2.1 and 1.5 for [18F]fluciclovine and [18F]FDG. The lesion SUVmax and ratios were significantly higher for [18F]fluciclovine (all p < 0.01). Local [18F]fluciclovine SUVmax or SUVmean values in os ilium and the percentage of plasma cells in bone marrow biopsies were linearly correlated (p = 0.048). There were no significant correlations between [18F]FDG SUVs and plasma cells (p = 0.82). CONCLUSIONS: Based on this pilot study, [18F]fluciclovine is a promising tracer for MM. The visual and semi-quantitative evaluations indicate that [18F]fluciclovine PET/CT can out-perform [18F]FDG PET/CT at diagnosis.
PURPOSE: [18F]FDG PET/CT in multiple myeloma (MM) is currently the best technology to demonstrate patchy and extramedullary disease. However, [18F]FDG PET has some limitations, and imaging with alternative tracers should be explored. In this study, we aimed to evaluate the performance of [18F]fluciclovine PET compared to [18F]FDG PET in newly diagnosed MM patients. PROCEDURES: Thirteen newly diagnosed transplant eligible MM patients were imaged both with [18F]FDG PET/CT and [18F]fluciclovine PET/CT within 1 week in a prospective study. The subjects were visually assessed positive or negative for disease. The number of lesions and the SUVmax of selected lesions were measured for both tracers. Furthermore, tracer uptake ratios were obtained by dividing lesion SUVmax by blood or bone marrow SUVmax. Between-group differences and correlations were assessed with paired t-tests and Pearson tests. Bone marrow SUVs were compared to bone marrow plasma cell percentage in biopsy samples. RESULTS: Nine subjects were assessed positively by [18F]FDG PET (69%) and 12 positives by [18F]fluciclovine PET (92%). All positive subjects had [18F]fluciclovine scans that were qualitatively scored as easier to interpret visually than the [18F]FDG scans. The number of lesions was also higher; seven of nine subjects with distinct hot spots on [18F]fluciclovine PET had fewer or no visible lesions on [18F]FDG PET. The mean lesion SUVmax values were 8.2 and 3.8 for [18F]fluciclovine and [18F]FDG, respectively. The mean tumour to blood values were 6.4 and 2.0 for [18F]fluciclovine and [18F]FDG, and the mean ratios between tumour and bone marrow were 2.1 and 1.5 for [18F]fluciclovine and [18F]FDG. The lesion SUVmax and ratios were significantly higher for [18F]fluciclovine (all p < 0.01). Local [18F]fluciclovine SUVmax or SUVmean values in os ilium and the percentage of plasma cells in bone marrow biopsies were linearly correlated (p = 0.048). There were no significant correlations between [18F]FDG SUVs and plasma cells (p = 0.82). CONCLUSIONS: Based on this pilot study, [18F]fluciclovine is a promising tracer for MM. The visual and semi-quantitative evaluations indicate that [18F]fluciclovine PET/CT can out-perform [18F]FDG PET/CT at diagnosis.
Authors: Masahiro Ono; Shuntaro Oka; Hiroyuki Okudaira; David M Schuster; Mark M Goodman; Keiichi Kawai; Yoshifumi Shirakami Journal: Brain Res Date: 2013-08-27 Impact factor: 3.252
Authors: Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Rosa Fonti; Michele Larobina; Silvana Del Vecchio; Serena De Luca; Rossella Fabbricini; Lucio Catalano; Fabrizio Pane; Marco Salvatore; Leonardo Pace Journal: J Nucl Med Date: 2012-10-15 Impact factor: 10.057
Authors: Gary A Ulaner; Debra A Goldman; Mithat Gönen; Hanh Pham; Raychel Castillo; Serge K Lyashchenko; Jason S Lewis; Chau Dang Journal: J Nucl Med Date: 2016-03-03 Impact factor: 10.057
Authors: Jonathon A Nye; David M Schuster; Weiping Yu; Vernon M Camp; Mark M Goodman; John R Votaw Journal: J Nucl Med Date: 2007-05-15 Impact factor: 10.057
Authors: Constantin Lapa; Maria J Garcia-Velloso; Katharina Lückerath; Samuel Samnick; Martin Schreder; Paula Rodriguez Otero; Jan-Stefan Schmid; Ken Herrmann; Stefan Knop; Andreas K Buck; Hermann Einsele; Jesus San-Miguel; Klaus Martin Kortüm Journal: Theranostics Date: 2017-07-23 Impact factor: 11.556
Authors: Maria I Morales-Lozano; Oliver Viering; Samuel Samnick; Paula Rodriguez-Otero; Andreas K Buck; Maria Marcos-Jubilar; Leo Rasche; Elena Prieto; K Martin Kortüm; Jesus San-Miguel; Maria J Garcia-Velloso; Constantin Lapa Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639